+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients



Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients



American Journal of Hypertension 13(12): 1295-1300



AT1 receptor antagonists control blood pressure (BP) effectively and reduce left ventricular hypertrophy in patients with essential hypertension. Because left ventricular hypertrophy is very common in renal transplant recipients, we examined the cardiovascular effects and the safety profile of the AT1 receptor antagonist losartan in hypertensive renal transplant recipients. In 20 renal transplant recipients with stable renal graft function 50 mg of losartan was added to the preexisting antihypertensive treatment (no angiotensin-converting enzyme inhibitors) at least 6 months after renal transplantation. Twenty-four-hour ambulatory BP, two-dimensional-guided M-mode echocardiography, and duplex sonography, as well as renal function, red blood cell count, cyclosporine A and FK 506 levels, erythropoetin, and angiotensin II concentration were determined at baseline and after 6 months of therapy. With 24-h ambulatory BP measurement, systolic blood pressure (SBP) was reduced by 7.5 +/- 2.4 mm Hg and diastolic blood pressure (DBP) by 4.5 +/- 1.8 mm Hg (P < .01 and P < .05, respectively). Posterior, septal, and relative wall thickness decreased by 0.95 +/- 0.2 mm, 0.91 +/- 0.2 mm and 0.04 +/- 0.01 mm, respectively (all P < .001). Left ventricular mass index decreased by 18.1 +/- 4.7 g/m2 (P < .01). Ejection fraction and midwall fractional fiber shortening as systolic parameters and the relation of passive-to-active diastolic filling of the left ventricle were unaltered. Serum creatinine and cyclosporine A concentration remained stable in all patients. Hemoglobin and hematocrit decreased by 1.0 +/- 0.3 g/dL and 3.6% +/- 0.9%, respectively (P < .002 and P < .001) without a change in serum erythropoetin level. In renal transplant recipients the AT1 receptor antagonist losartan reduces left ventricular hypertrophy without altering systolic or diastolic function. It is safe with regard to renal function and immunosuppression, but slightly decreases hemoglobin level.

(PDF emailed within 0-6 h: $19.90)

Accession: 011265716

Download citation: RISBibTeXText

PMID: 11130774

DOI: 10.1016/s0895-7061(00)01213-9


Related references

Regression of left ventricular hypertrophy after arteriovenous fistula closure in renal transplant recipients: a long-term follow-up. American Journal of Transplantation 4(12): 2038-2044, 2004

Regression and prevention of left ventricular hypertrophy are possible in hypertensive heart transplant recipients. Journal of the American College of Cardiology 15(2 SUPPL A): 223A, 1990

Left ventricular hypertrophy and left ventricular diastolic dysfunction in renal transplant recipients An echocardiographic assessment. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 712A, Sept, 1997

Prevalence of Left Ventricular Hypertrophy and Left Ventricular Dysfunction in Older Renal Transplant Recipients. Transplantation Proceedings 48(5): 1641-1643, 2017

Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade The LIFE trial. American Journal of Hypertension 15(4 Part 2): 15A, 2002

Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation 84(2): 583-593, 1991

Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. Transplantation Proceedings 42(9 Suppl): S41-S43, 2011

Left ventricular hypertrophy in renal transplant recipients in the first year after transplantation. Transplantation Proceedings 46(8): 2719-2723, 2015

Left ventricular hypertrophy and pulse pressure in renal transplant recipients. American Journal of Hypertension 14(4 Part 2): 86A-87A, 2001

The relationship between hypertension and left ventricular hypertrophy in renal transplant recipients. Transplantation Proceedings 20(6): 1221-1224, 1988

Regression of left ventricular hypertrophy by losartan in renal transplant patients. Kidney & Blood Pressure Research 21(2-4): 112, 1998

Ultrasonic regression of left ventricular hypertrophy is associated with a decrease in morphometrically determined myocyte size in hypertensive heart transplant recipients. Circulation 88(4 PART 2): I615, 1993

The role of angiotensin receptor-1 blockade on electromechanical changes induced by left ventricular hypertrophy and its regression. Cardiovascular Research 73(3): 539-548, 2006

Effect of systemic hypertension on renal function and left ventricular hypertrophy in heart transplant recipients. Journal of the American College of Cardiology 15(5): 1095-1101, 1990